Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting.

Seung Il Jung Myung Soo Kim Chang Wook Jeong Cheol Kwak Sung Kyu Hong Seok Ho Kang Jae Young Joung Seung Hwan Lee Seok-Joong Yun Tae Hwan Kim Sung Woo Park Seong Soo Jeon Minyong Kang Ji Youl Lee Byung Ha Chung Jun Hyuk Hong Hanjong Ahn Choung-Soo Kim Dong Deuk Kwon

Published in: Investigative and clinical urology (2019)

Enzalutamide is effective and safe for chemotherapy-naïve patients with mCRPC. Furthermore, the overall survival was significantly higher in patients receiving enzalutamide and concurrent ADT than in patients receiving enzalutamide alone.

Keyphrases

prostate cancer
locally advanced
squamous cell carcinoma
rectal cancer
hiv infected
radiation therapy